- Home
- ARCO vs ARQT Comparison
ARCO vs ARQT Comparison
Compare ARCO & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARCO
- ARQT
- Stock Information
- Founded
- ARCO 2007
- ARQT 2016
- Country
- ARCO Uruguay
- ARQT United States
- Employees
- ARCO N/A
- ARQT N/A
- Industry
- ARCO Restaurants
- ARQT Biotechnology: Pharmaceutical Preparations
- Sector
- ARCO Consumer Discretionary
- ARQT Health Care
- Exchange
- ARCO Nasdaq
- ARQT Nasdaq
- Market Cap
- ARCO 1.7B
- ARQT 2.0B
- IPO Year
- ARCO 2011
- ARQT 2020
- Fundamental
- Price
- ARCO $7.33
- ARQT $14.68
- Analyst Decision
- ARCO Buy
- ARQT Strong Buy
- Analyst Count
- ARCO 1
- ARQT 6
- Target Price
- ARCO $12.00
- ARQT $18.80
- AVG Volume (30 Days)
- ARCO 1.4M
- ARQT 2.7M
- Earning Date
- ARCO 05-14-2025
- ARQT 05-13-2025
- Dividend Yield
- ARCO 3.00%
- ARQT N/A
- EPS Growth
- ARCO N/A
- ARQT N/A
- EPS
- ARCO 0.71
- ARQT N/A
- Revenue
- ARCO $4,470,162,000.00
- ARQT $196,542,000.00
- Revenue This Year
- ARCO $6.53
- ARQT $56.84
- Revenue Next Year
- ARCO $8.99
- ARQT $44.87
- P/E Ratio
- ARCO $11.67
- ARQT N/A
- Revenue Growth
- ARCO 3.19
- ARQT 229.74
- 52 Week Low
- ARCO $7.02
- ARQT $6.99
- 52 Week High
- ARCO $11.49
- ARQT $17.75
- Technical
- Relative Strength Index (RSI)
- ARCO 40.80
- ARQT 50.18
- Support Level
- ARCO $7.90
- ARQT $14.51
- Resistance Level
- ARCO $8.32
- ARQT $17.43
- Average True Range (ATR)
- ARCO 0.22
- ARQT 1.09
- MACD
- ARCO -0.04
- ARQT -0.17
- Stochastic Oscillator
- ARCO 4.53
- ARQT 28.09
About ARCO Arcos Dorados Holdings Inc. Shares
Arcos Dorados Holdings Inc operates McDonald's-branded restaurants in approximately 20 countries and territories in Latin America and the Caribbean. It functions through two sources which include company-operated restaurants and franchised restaurants segment. Their menu includes hamburgers, McNuggets, salad, sandwiches, french fries and others.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.